Rituxan Approved For First-Line Non-Hodgkin's Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
A second sBLA is pending for the treatment of refractory rheumatoid arthritis.
You may also be interested in...
Rituxan Adds Third NHL Indication In 2006
The Genentech/Biogen Idec oncologic, first approved in 1997, is now also approved for first-line with CVP and ongoing treatment of stable disease.
Rituxan Adds Third NHL Indication In 2006
The Genentech/Biogen Idec oncologic, first approved in 1997, is now also approved for first-line with CVP and ongoing treatment of stable disease.
Rituxan Comes In Like A Lion With Two New Indications
FDA clears Genentech/Biogen Idec’s oncologic Rituxan for rheumatoid arthritis weeks after it was approved for first-line non-Hodgkins lymphoma.